In an effort to produce further direct experimental evidence supporting the above hypothesis, in this report, we have evaluated the effect of specific SOS1 and/or SOS2 genetic ablation on a mouse model of p210BCR/ABL-driven CML. The gene discussed is ABL1; the disease is chronic myelogenous leukemia, BCR-ABL1 positive.